Safety and Challenges of Pregnancy in Women with a History of Endocrine-Sensitive Breast Cancer

  • Hatem A. AzimJr


Studies have shown that an increasing proportion of young women are diagnosed with breast cancer before completing their families. However, there is a dogma that subsequent pregnancy could be detrimental on breast cancer outcome. Over the past 40 years, several studies were published showing that pregnancy does not appear to increase the risk of recurrence. More recently, we have shown in a large international trial that even in patients with a history of endocrine-sensitive disease, subsequent pregnancy appears to be safe. However, with the increasing duration of adjuvant endocrine therapies (sometimes up to 10 years), it is mostly unfeasible to wait that long to consider a pregnancy. This chapter discusses how to counsel and manage these situations. It also discusses pregnancy and fetal risks along with managing pregnancies occurring accidentally during adjuvant endocrine treatment.


Pregnancy Breast cancer Estrogen receptor Fertility Recurrence Malformations Hormonal therapy 


  1. 1.
    Rosenberg SM, Newman LA, Partridge AH. Breast cancer in young women: rare disease or public health problem? JAMA Oncol. 2015;1:877–8.CrossRefGoogle Scholar
  2. 2.
    Azim HA Jr, Peccatori FA, de Azambuja E, et al. Motherhood after breast cancer: searching for la dolce vita. Expert Rev Anticancer Ther. 2011;11:287–98.CrossRefGoogle Scholar
  3. 3.
    Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–83.CrossRefGoogle Scholar
  4. 4.
    Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32:1151–6.CrossRefGoogle Scholar
  5. 5.
    Lambertini M, Di Maio M, Pagani O, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41–9.CrossRefGoogle Scholar
  6. 6.
    Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131:1061–6.CrossRefGoogle Scholar
  7. 7.
    Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341–51.CrossRefGoogle Scholar
  8. 8.
    Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18.CrossRefGoogle Scholar
  9. 9.
    Francis PA, Regan MM, Fleming GF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:1673.CrossRefGoogle Scholar
  10. 10.
    Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.CrossRefGoogle Scholar
  11. 11.
    Stensheim H, Cvancarova M, Moller B, et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129:1225–36.CrossRefGoogle Scholar
  12. 12.
    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–70.CrossRefGoogle Scholar
  13. 13.
    Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47:74–83.CrossRefGoogle Scholar
  14. 14.
    Biglia N, Torrisi R, D’Alonzo M, et al. Attitudes on fertility issues in breast cancer patients: an Italian survey. Gynecol Endocrinol. 2015;31:458–64.CrossRefGoogle Scholar
  15. 15.
    Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31:73–9.CrossRefGoogle Scholar
  16. 16.
    Lambertini M, Kroman N, Ameye L, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018;110:426–9.CrossRefGoogle Scholar
  17. 17.
    Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;31:3083–90.CrossRefGoogle Scholar
  18. 18.
    Pagani O, Ruggeri M, Manunta S, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24:201–7.CrossRefGoogle Scholar
  19. 19.
    Huiart L, Bouhnik AD, Rey D, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48:1939–46.CrossRefGoogle Scholar
  20. 20.
    Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23:882–90.CrossRefGoogle Scholar
  21. 21.
    Langagergaard V, Gislum M, Skriver MV, et al. Birth outcome in women with breast cancer. Br J Cancer. 2006;94:142–6.CrossRefGoogle Scholar
  22. 22.
    Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer—a population-based cohort study from Sweden. PLoS Med. 2006;3:e336.CrossRefGoogle Scholar
  23. 23.
    Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133:387–91.CrossRefGoogle Scholar
  24. 24.
    Lambertini M, Martel S, Campbell C, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019;125:307–16.CrossRefGoogle Scholar
  25. 25.
    Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349–64.CrossRefGoogle Scholar
  26. 26.
    Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1.CrossRefGoogle Scholar
  27. 27.
    Sharma S, Rani G, Bose G, et al. Tamoxifen is better than low-dose clomiphene or gonadotropins in women with thin endometrium (<7 mm) after clomiphene in intrauterine insemination cycles: a prospective study. J Hum Reprod Sci. 2018;11:34–9.CrossRefGoogle Scholar
  28. 28.
    Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16:1547–51.CrossRefGoogle Scholar
  29. 29.
    Tewari K, Bonebrake RG, Asrat T, et al. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997;350:183.CrossRefGoogle Scholar
  30. 30.
    Cullins SL, Pridjian G, Sutherland CM. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA. 1994;271:1905–6.CrossRefGoogle Scholar
  31. 31.
    Berger JC, Clericuzio CL. Pierre Robin sequence associated with first trimester fetal tamoxifen exposure. Am J Med Genet A. 2008;146A:2141–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Hatem A. AzimJr
    • 1
  1. 1.Tecnologico de Monterrey, School of MedicineMonterreyMéxico

Personalised recommendations